InvestSMART

Argent Biopharma Limited (ASX: RGT) - Announcements

- Current share price for RGT : $0.032

ASX company news and announcements for Argent Biopharma Limited (RGT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argent Biopharma Limited (RGT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argent Biopharma Limited (RGT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argent Biopharma Limited (RGT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$4 Notification regarding unquoted securities - RGT 10 Apr 2026 6:19PM $0.033 $0.032 fallen by 3.03%
$4 Application for quotation of securities - RGT 10 Apr 2026 6:18PM $0.033 $0.032 fallen by 3.03%
$4 Application for quotation of securities - RGT 10 Apr 2026 6:18PM $0.033 $0.032 fallen by 3.03%
$4 Application for quotation of securities - RGT 10 Apr 2026 6:18PM $0.033 $0.032 fallen by 3.03%
$4 Results of Meeting 8 Apr 2026 12:45PM $0.040 $0.032 fallen by 20%
$4 s708A Cleansing Notice 20 Mar 2026 3:09PM $0.041 $0.032 fallen by 21.95%
$4 Application for quotation of securities - RGT 20 Mar 2026 3:09PM $0.041 $0.032 fallen by 21.95%
$4 Notification regarding unquoted securities - RGT 20 Mar 2026 3:05PM $0.041 $0.032 fallen by 21.95%
$4 Notification regarding unquoted securities - RGT 20 Mar 2026 3:04PM $0.041 $0.032 fallen by 21.95%
$4 Notice of General Meeting/Proxy Form 6 Mar 2026 1:22PM $0.046 $0.032 fallen by 30.43%
$4 s708A Cleansing Notice 27 Feb 2026 6:16PM $0.056 $0.032 fallen by 42.86%
$4 Application for quotation of securities - RGT 27 Feb 2026 6:15PM $0.056 $0.032 fallen by 42.86%
$4 Half Yearly Report and Accounts 27 Feb 2026 6:15PM $0.056 $0.032 fallen by 42.86%
$4 Provisional Patent Lodged with USPTO for NanoBodies Platform 25 Feb 2026 9:29AM $0.055 $0.032 fallen by 41.82%
$4 CannEpil - Largest Commercial Shipment Arrives in Ireland 23 Feb 2026 9:31AM $0.051 $0.032 fallen by 37.25%
$4 s708A Cleansing Notice 10 Feb 2026 4:40PM $0.056 $0.032 fallen by 42.86%
$4 Application for quotation of securities - RGT 10 Feb 2026 4:38PM $0.056 $0.032 fallen by 42.86%
$4 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 8:15AM $0.056 $0.032 fallen by 42.86%
$4 s708A Cleansing Notice 15 Jan 2026 5:20PM $0.059 $0.032 fallen by 45.76%
$4 Application for quotation of securities - RGT 15 Jan 2026 5:17PM $0.059 $0.032 fallen by 45.76%
$4 Proposed issue of securities - RGT 14 Jan 2026 9:27AM $0.060 $0.032 fallen by 46.67%
$4 Streamlined Acquisition of AusCann Assets 14 Jan 2026 9:26AM $0.060 $0.032 fallen by 46.67%
$4 s708A Cleansing Notice 12 Dec 2025 7:22PM $0.069 $0.032 fallen by 53.62%
$4 Application for quotation of securities - RGT 12 Dec 2025 7:21PM $0.069 $0.032 fallen by 53.62%
$4 Application for quotation of securities - RGT 12 Dec 2025 7:21PM $0.069 $0.032 fallen by 53.62%

26 - 50 of 172 results

Page 2 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.